@article {Simard2021.01.29.21250770, author = {Carl Simard and Jonathan Richard and Ren{\'e}e Bazin and Andr{\'e}s Finzi and Patrick Tr{\'e}panier}, title = {Standardization of a flow cytometry SARS-CoV-2 serologic test}, elocation-id = {2021.01.29.21250770}, year = {2021}, doi = {10.1101/2021.01.29.21250770}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The SARS-CoV-2 virus is the causing agent of the coronavirus disease 2019 (COVID-19) pandemic which is responsible for millions of deaths worldwide. The development of the humoral response to the virus has been the subject of intensive research and development. A flow cytometry-based assay using native full-length SARS-CoV-2 Spike protein expressed in 293T cells was recently proposed as a complementary seropositivity determination assay.The aim of our study was to further develop the flow cytometry assay for potential use as a confirmatory test and to standardize its parameters and results for reliable inter-laboratory use. We have optimized the protocol, established the Receiving Operating Characteristic (ROC) curve and tested reproducibility using pre-COVID plasma samples and convalescent, SARS-CoV-2 individual plasma samples.The flow-based assay was simplified and standardized by cultivating the 293T cells in suspension and expressing results in Mean Equivalent Soluble Fluorochrome (MESF) using an internal antibody positive control. The ROC curve was determined with an area under the curve (AUC) of 0.996 and the assay specificity and sensitivity were established at 100\% and 97.7\% respectively. Reproducibility was good as determined on multiple cytometers, on different days, and with data acquisition as far as 72h post-staining. The optimized and standardized assay could be used as a high throughput confirmation confirmatory assay in flow cytometry laboratories involved in serological testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFundings This work was supported by le Ministere de l Economie et de l Innovation du Quebec Programme de soutien aux organismes de recherche et d innovation and by the Fondation du CHUM to A.F. This work was also supported by Canada s COVID-19 Immunity Task Force (CITF), in collaboration with the Canadian Institutes of Health Research (CIHR) and a CIHR foundation grant $\#$352417 to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. The funders had no role in study design data collection and analysis, decision to publish or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All donors gave consent to participate in this research project which was approved by the Hema-Quebec Research Ethic Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additionnal datasets are available.(ACE2)angiotensin-converting enzyme 2(AUC)area under the curve(COVID-19)coronavirus disease 2019(MESF)Mean Equivalent Soluble Fluorochrome(PCR)polymerase chain reaction(ROC)receiving operating characteristic(RBD)receptor-binding domain}, URL = {https://www.medrxiv.org/content/early/2021/02/01/2021.01.29.21250770}, eprint = {https://www.medrxiv.org/content/early/2021/02/01/2021.01.29.21250770.full.pdf}, journal = {medRxiv} }